Biosynex Financials
| ALBIO Stock | EUR 2.88 0.06 2.13% |
Biosynex |
Understanding current and past Biosynex Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biosynex's financial statements are interrelated, with each one affecting the others. For example, an increase in Biosynex's assets may result in an increase in income on the income statement.
Biosynex Stock Summary
Biosynex competes with Novacyt, Eurobio Scientific, Biophytis, and Intrasense. Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France. BIOSYNEX is traded on Paris Stock Exchange in France.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0011005933 |
| Business Address | 22 Boulevard Sbastien |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.biosynex.com |
| Phone | 33 3 88 78 78 87 |
| Currency | EUR - Euro |
You should never invest in Biosynex without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Biosynex Stock, because this is throwing your money away. Analyzing the key information contained in Biosynex's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Biosynex Key Financial Ratios
Biosynex's financial ratios allow both analysts and investors to convert raw data from Biosynex's financial statements into concise, actionable information that can be used to evaluate the performance of Biosynex over time and compare it to other companies across industries.Biosynex Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biosynex's current stock value. Our valuation model uses many indicators to compare Biosynex value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biosynex competition to find correlations between indicators driving Biosynex's intrinsic value. More Info.Biosynex is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biosynex is roughly 2.00 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biosynex's earnings, one of the primary drivers of an investment's value.Biosynex Systematic Risk
Biosynex's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biosynex volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Biosynex correlated with the market. If Beta is less than 0 Biosynex generally moves in the opposite direction as compared to the market. If Biosynex Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biosynex is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biosynex is generally in the same direction as the market. If Beta > 1 Biosynex moves generally in the same direction as, but more than the movement of the benchmark.
Biosynex November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biosynex help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biosynex. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biosynex based on widely used predictive technical indicators. In general, we focus on analyzing Biosynex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biosynex's daily price indicators and compare them against related drivers.
| Information Ratio | (0.28) | |||
| Maximum Drawdown | 24.51 | |||
| Value At Risk | (6.47) | |||
| Potential Upside | 5.69 |
Additional Tools for Biosynex Stock Analysis
When running Biosynex's price analysis, check to measure Biosynex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosynex is operating at the current time. Most of Biosynex's value examination focuses on studying past and present price action to predict the probability of Biosynex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosynex's price. Additionally, you may evaluate how the addition of Biosynex to your portfolios can decrease your overall portfolio volatility.